{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T13:17:41Z","timestamp":1791119861465,"version":"4.1.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T00:00:00Z","timestamp":1700870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009270","name":"Invention for Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009270","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AMLo"},{"name":"AMLo Biosciences Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Combined expression of the autophagy-regulatory protein AMBRA1 (activating molecule in Beclin1-regulated autophagy) and the terminal differentiation marker loricrin in the peritumoral epidermis of stage I melanomas can identify tumour subsets at low risk of \u00admetastasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To validate the combined expression of peritumoral AMBRA1 and loricrin (AMBLor) as a prognostic biomarker able to identify both stage I and II melanomas at low risk of tumour recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Automated immunohistochemistry was used to analyse peritumoral AMBRA1 and loricrin expression in geographically distinct discovery (n = 540) and validation (n = 300) cohorts of nonulcerated American Joint Committee on Cancer (AJCC) stage I and II melanomas. AMBLor status was correlated with clinical outcomes in the discovery and validation cohorts separately and combined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Analysis of AMBLor in the discovery cohort revealed a recurrence-free survival (RFS) rate of 95.5% in the AMBLor low-risk group vs. 81.7% in the AMBLor at-risk group (multivariate log-rank, P &amp;lt; 0.001) and a negative predictive value (NPV) of 96.0%. In the validation cohort, AMBLor analysis revealed a RFS rate of 97.6% in the AMBLor low-risk group vs. 78.3% in the at-risk group (multivariate log-rank, P &amp;lt; 0.001) and a NPV of 97.6%. In a multivariate model considering AMBLor, Breslow thickness, age and sex, analysis of the combined discovery and validation cohorts showed that the estimated effect of AMBLor was statistically significant, with a hazard ratio of 3.469 (95% confidence interval 1.403\u20138.580, P = 0.007) and an overall NPV of 96.5%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These data provide further evidence validating AMBLor as a prognostic biomarker to identify nonulcerated AJCC stage I and II melanoma tumours at low risk of disease recurrence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljad459","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T17:51:33Z","timestamp":1700761893000},"page":"549-558","source":"Crossref","is-referenced-by-count":14,"title":["Validation of epidermal AMBRA1 and loricrin (AMBLor) as a prognostic biomarker for nonulcerated American Joint Committee on Cancer stage I\/II cutaneous melanoma"],"prefix":"10.1093","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9178-9614","authenticated-orcid":false,"given":"Tom","family":"Ewen","sequence":"first","affiliation":[{"name":"Translation and Clinical Research Institute, Newcastle University , Newcastle upon Tyne , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhtar","family":"Husain","sequence":"additional","affiliation":[{"name":"Novo Path and Cellular Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niki","family":"Stefanos","sequence":"additional","affiliation":[{"name":"Pathology, Addenbrookes Hospital, Cambridge University NHS Trust , Cambridge , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Barrett","sequence":"additional","affiliation":[{"name":"Pathology, University Hospitals of North Durham , Durham , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Jones","sequence":"additional","affiliation":[{"name":"Novo Path and Cellular Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Ness","sequence":"additional","affiliation":[{"name":"Novo Path and Cellular Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Long","sequence":"additional","affiliation":[{"name":"Novo Path and Cellular Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Horswell","sequence":"additional","affiliation":[{"name":"Translation and Clinical Research Institute, Newcastle University , Newcastle upon Tyne , UK"},{"name":"Francis Crick Institute , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Bosomworth","sequence":"additional","affiliation":[{"name":"Translation and Clinical Research Institute, Newcastle University , Newcastle upon Tyne , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Lowenstein","sequence":"additional","affiliation":[{"name":"Translation and Clinical Research Institute, Newcastle University , Newcastle upon Tyne , UK"},{"name":"AMLo Biosciences , Newcastle upon Tyne , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"Richardson","sequence":"additional","affiliation":[{"name":"Translation and Clinical Research Institute, Newcastle University , Newcastle upon Tyne , UK"},{"name":"AMLo Biosciences , Newcastle upon Tyne , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Swan","sequence":"additional","affiliation":[{"name":"AMLo Biosciences , Newcastle upon Tyne , UK"},{"name":"Faculty of Health Sciences and Wellbeing, University of Sunderland , Sunderland , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashleigh","family":"McConnell","sequence":"additional","affiliation":[{"name":"Translation and Clinical Research Institute, Newcastle University , Newcastle upon Tyne , UK"},{"name":"AMLo Biosciences , Newcastle upon Tyne , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidan","family":"Rose","sequence":"additional","affiliation":[{"name":"Translation and Clinical Research Institute, Newcastle University , Newcastle upon Tyne , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Andrew","sequence":"additional","affiliation":[{"name":"Translation and Clinical Research Institute, Newcastle University , Newcastle upon Tyne , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Translation and Clinical Research Institute, Newcastle University , Newcastle upon Tyne , UK"},{"name":"Department of Dermatology and NIHR Newcastle Biomedical Research Centre , Royal Victoria Infirmary , Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Malvehy","sequence":"additional","affiliation":[{"name":"Hospital Clinic Barcelona, University of Barcelona , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Carrera","sequence":"additional","affiliation":[{"name":"Hospital Clinic Barcelona, University of Barcelona , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Llucia","family":"Alos","sequence":"additional","affiliation":[{"name":"Hospital Clinic Barcelona, University of Barcelona , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Mailer","sequence":"additional","affiliation":[{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne , Melbourne, VIC , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Helm","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Buffalo Medical Group , Williamsville, NY , USA"},{"name":"Department of Dermatology, Penn State Hershey , Hershey, Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Pathology, Roswell Park Comprehensive Cancer Center , Buffalo, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Bogner","sequence":"additional","affiliation":[{"name":"Department of Pathology, Roswell Park Comprehensive Cancer Center , Buffalo, NY , USA"},{"name":"Department of Dermatology, Roswell Park Comprehensive Cancer Center , Buffalo, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Podlipnik","sequence":"additional","affiliation":[{"name":"Hospital Clinic Barcelona, University of Barcelona , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1337-9745","authenticated-orcid":false,"given":"Susana","family":"Puig","sequence":"additional","affiliation":[{"name":"Hospital Clinic Barcelona, University of Barcelona , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant A","family":"McArthur","sequence":"additional","affiliation":[{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne , Melbourne, VIC , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyorgy","family":"Paragh","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Roswell Park Comprehensive Cancer Center , Buffalo, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Labus","sequence":"additional","affiliation":[{"name":"Translation and Clinical Research Institute, Newcastle University , Newcastle upon Tyne , UK"},{"name":"AMLo Biosciences , Newcastle upon Tyne , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Sloan","sequence":"additional","affiliation":[{"name":"Translation and Clinical Research Institute, Newcastle University , Newcastle upon Tyne , UK"},{"name":"Novo Path and Cellular Pathology"},{"name":"AMLo Biosciences , Newcastle upon Tyne , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5822-0597","authenticated-orcid":false,"given":"Jane L","family":"Armstrong","sequence":"additional","affiliation":[{"name":"AMLo Biosciences , Newcastle upon Tyne , UK"},{"name":"Faculty of Health Sciences and Wellbeing, University of Sunderland , Sunderland , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6657-6825","authenticated-orcid":false,"given":"Penny E","family":"Lovat","sequence":"additional","affiliation":[{"name":"Translation and Clinical Research Institute, Newcastle University , Newcastle upon Tyne , UK"},{"name":"AMLo Biosciences , Newcastle upon Tyne , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,11,25]]},"reference":[{"key":"2024090210043067900_ljad459-B1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global burden of cutaneous melanoma in 2020 and projections to 2040","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2024090210043067900_ljad459-B2","author":"Cancer Research UK"},{"key":"2024090210043067900_ljad459-B3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1200\/OP.21.00686","article-title":"Managing metastatic melanoma in 2022: a clinical review","volume":"18","author":"Switzer","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"2024090210043067900_ljad459-B4","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/jid.2014.452","article-title":"More people die from thin melanomas (\u22641\u2005mm) than from thick melanomas (&gt;4\u2005mm) in Queensland, Australia","volume":"135","author":"Whiteman","year":"2015","journal-title":"J Invest Dermatol"},{"key":"2024090210043067900_ljad459-B5","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"2024090210043067900_ljad459-B6","author":"NHS Digital"},{"key":"2024090210043067900_ljad459-B7","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/CMR.0000000000000489","article-title":"Stage-specific incidence trends of melanoma in an English region, 1996\u2013\u200c2015: longitudinal analyses of population-based data","volume":"30","author":"Herbert","year":"2020","journal-title":"Melanoma Res"},{"key":"2024090210043067900_ljad459-B8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejca.2021.06.007","article-title":"Stage-specific trends in incidence and survival of cutaneous melanoma in the Netherlands (2003\u20132018): a nationwide population-based study","volume":"154","author":"Leeneman","year":"2021","journal-title":"Eur J Cancer"},{"key":"2024090210043067900_ljad459-B9","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/jnci\/djaa008","article-title":"Melanoma prognosis: accuracy of the American Joint Committee on Cancer Staging Manual Eighth Edition","volume":"112","author":"Bajaj","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"2024090210043067900_ljad459-B10","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.22.00202","article-title":"Prognosis of patients with primary melanoma stage I and II according to American Joint Committee on Cancer Version 8 validated in two independent cohorts: implications for adjuvant treatment","volume":"40","author":"Garbe","year":"2022","journal-title":"J Clin Oncol"},{"key":"2024090210043067900_ljad459-B11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41698-022-00321-4","article-title":"Prediction of early-stage melanoma recurrence using clinical and histopathologic features","volume":"6","author":"Wan","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"2024090210043067900_ljad459-B12","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/phpp.12770","article-title":"Prognostic biomarkers of cutaneous melanoma","volume":"38","author":"Ding","year":"2022","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"2024090210043067900_ljad459-B13","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"key":"2024090210043067900_ljad459-B14","author":"National Institute for Health and Care Excellence"},{"key":"2024090210043067900_ljad459-B15","doi-asserted-by":"crossref","DOI":"10.2217\/mmt-2017-0028","article-title":"Real-world experience with pembrolizumab toxicities in advanced melanoma patients: a single-center experience in the UK","volume":"5","author":"So","year":"2018","journal-title":"Melanoma Manag"},{"key":"2024090210043067900_ljad459-B16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/jamadermatol.2021.5476","article-title":"Association of cutaneous immune-\u00adrelated adverse events with increased survival in patients treated with anti-programmed cell death 1 and anti-programmed cell death ligand 1 therapy","volume":"158","author":"Tang","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2024090210043067900_ljad459-B17","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.amjsurg.2011.06.048","article-title":"Prognostic implications of anatomic location of primary cutaneous melanoma of 1\u2005mm or thicker","volume":"202","author":"Callender","year":"2011","journal-title":"Am J Surg"},{"key":"2024090210043067900_ljad459-B18","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/jnci\/djy086","article-title":"Primary melanoma histologic subtype: impact on survival and response to therapy","volume":"111","author":"Lattanzi","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"2024090210043067900_ljad459-B19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/CMR.0000000000000302","article-title":"Prospective evaluation of prognostic indicators for early recurrence of cutaneous melanoma","volume":"27","author":"Matheson","year":"2017","journal-title":"Melanoma Res"},{"key":"2024090210043067900_ljad459-B20","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1001\/jamadermatol.2019.0440","article-title":"Risk of melanoma recurrence after diagnosis of a high-risk primary tumor","volume":"155","author":"von Schuckmann","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2024090210043067900_ljad459-B21","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s13555-022-00709-x","article-title":"Expert consensus on the use of prognostic gene expression profiling tests for the management of cutaneous melanoma: consensus from the Skin Cancer Prevention Working Group","volume":"12","author":"Farberg","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2024090210043067900_ljad459-B22","first-page":"156","article-title":"Epidermal autophagy and beclin 1 regulator 1 and loricrin: a paradigm shift in the prognostication and stratification of the American Joint Committee on Cancer stage I melanomas","volume":"182","author":"Ellis","year":"2020","journal-title":"Br J Dermatol"},{"key":"2024090210043067900_ljad459-B23","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/bjd.20889","article-title":"Melanoma secretion of transforming growth factor-beta2 leads to loss of epidermal AMBRA1 threatening epidermal integrity and facilitating tumour ulceration","volume":"186","author":"Cosgarea","year":"2022","journal-title":"Br J Dermatol"},{"issue":"51","key":"2024090210043067900_ljad459-B24","article-title":"Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration","volume":"10","author":"Altman","year":"2012","journal-title":"BMC Med"},{"key":"2024090210043067900_ljad459-B25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5334\/ojb.47","article-title":"The Northern Ireland Biobank: a cancer focused repository of science","volume":"5","author":"Lewis","year":"2018","journal-title":"Open J Bioresour"},{"key":"2024090210043067900_ljad459-B26","author":"R Core Team"},{"key":"2024090210043067900_ljad459-B27","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(17)30677-0","article-title":"Cancer incidence and mortality among young adults aged 20\u201339\u2005years worldwide in 2012: a population-based study","volume":"18","author":"Fidler","year":"2017","journal-title":"Lancet Oncol"},{"key":"2024090210043067900_ljad459-B28","author":"National Cancer Institute"},{"key":"2024090210043067900_ljad459-B29","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaad.2016.10.018","article-title":"Mortality burden and prognosis of thin melanomas overall and by subcategory of thickness, SEER registry data, 1992\u20132013","volume":"76","author":"Landow","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2024090210043067900_ljad459-B30","first-page":"E61","article-title":"Risk stratification of patients with stage I cutaneous melanoma using 31-gene expression profiling","volume":"14","author":"Martin","year":"2021","journal-title":"J Clin Aesthet Dermatol"},{"key":"2024090210043067900_ljad459-B31","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12885-018-4016-3","article-title":"Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients","volume":"18","author":"Zager","year":"2018","journal-title":"BMC Cancer"},{"key":"2024090210043067900_ljad459-B32","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2217\/fon-2018-0912","article-title":"Guidance of sentinel lymph node biopsy decisions in patients with T1\u2013T2 melanoma using gene expression profiling","volume":"15","author":"Vetto","year":"2019","journal-title":"Future Oncol"},{"key":"2024090210043067900_ljad459-B33","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/PO.20.00119","article-title":"Long-term outcomes in a multicenter, prospective cohort evaluating the prognostic 31-gene expression profile for cutaneous melanoma","volume":"5","author":"Hsueh","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"2024090210043067900_ljad459-B34","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.jaad.2022.06.1202","article-title":"Optimizing treatment approaches for patients with cutaneous melanoma by integrating clinical and pathologic features with the 31-gene expression profile test","volume":"87","author":"Jarell","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2024090210043067900_ljad459-B35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejca.2020.08.029","article-title":"Identification of stage I\/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model","volume":"140","author":"Eggermont","year":"2020","journal-title":"Eur J Cancer"},{"key":"2024090210043067900_ljad459-B36","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2019.10.027","article-title":"Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma","volume":"125","author":"Amaral","year":"2020","journal-title":"Eur J Cancer"},{"key":"2024090210043067900_ljad459-B37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejca.2020.10.016","article-title":"Prognostic significance of an 11-gene RNA assay in archival tissue of cutaneous melanoma stage I\u2013\u200cIII patients","volume":"143","author":"Gambichler","year":"2021","journal-title":"Eur J Cancer"},{"key":"2024090210043067900_ljad459-B38","doi-asserted-by":"crossref","first-page":"e0265048","DOI":"10.1371\/journal.pone.0265048","article-title":"Health professional and patient views of a novel prognostic test for melanoma: a theoretically informed qualitative study","volume":"17","author":"Lecouturier","year":"2022","journal-title":"PLOS ONE"},{"key":"2024090210043067900_ljad459-B39","author":"National Institute for Health and Care Excellence"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljad459\/56761546\/ljad459.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/4\/549\/58993229\/ljad459.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/4\/549\/58993229\/ljad459.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T08:42:20Z","timestamp":1725266540000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/190\/4\/549\/7450982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,25]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,11,25]]},"published-print":{"date-parts":[[2024,3,15]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljad459","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2023,11,25]]}}}